[Special Stock] T&R Biofab Collaborates with Global No.1 J&J... Leading Artificial Tissue That Big Pharma Is Eyeing

[Asia Economy Reporter Hyungsoo Park] T&R Biofab is showing strong performance.

At 10:58 AM, T&R Biofab is trading at 20,250 KRW, up 3.32% from the previous day.

T&R Biofab announced that it has signed a strategic joint research agreement with Johnson & Johnson Innovation for the development of 3D bioprinting scaffold (biodegradable support) technology for tissue regeneration.

Through this agreement, T&R Biofab plans to develop implantable products based on various biomaterials and bio-synthetic polymer materials using its platform that utilizes 3D bioprinting technology.

The platform technology based on 3D bioprinting is characterized by meeting various mechanical strength standards while maintaining biocompatible safety. According to T&R Biofab, it can overcome the drawbacks of various materials currently used for tissue regeneration.

Yoon Wonsoo, CEO of T&R Biofab, said, "This joint development agreement is the second collaboration following the first joint research and development contract signed in 2020, and it is significant as it expands and concretizes various cooperative relationships between the two companies."

According to global data, the 3D printing industry size was about $11 billion in 2018, but it is expected to grow at an average annual rate of about 15%, reaching $32 billion by 2025 and $60 billion by 2030. On February 18, the FDA approved the use of 3D printed metal implants (ankle joint) for the first time. The use of 3D printing in the medical market is expected to become increasingly common in the future.

T&R Biofab's core 3D printing technology in the medical field is cell printing technology utilizing decellularized extracellular matrix (dECM) and induced pluripotent stem cell (iPSC) differentiation technology. Through the fusion of these technologies, they are developing simple organoids and bio-organs, and are developing artificial scaffolds using dECM as a single technology.

Byungguk Park, a researcher at NH Investment & Securities, explained, "J&J is expanding the use of 3D printing for artificial organs through a contract with FluidForm last year," adding, "Big pharma companies such as J&J, Sanofi, and AZ are securing capabilities for preclinical toxicity testing and drug development using artificial tissues and organoids."

This content was produced with the assistance of AI translation services.